PDGFRB and glioblastoma: In glioblastoma (GBM) cells, Willin/FRMD6 does not appear to activate the Hippo pathway, rather it inhibits activation of receptor tyrosine kinases including c-Met and PDGFR and their downstream ERK and AKT kinases [74].